2023 Q3 Form 10-Q Financial Statement
#000162828023026358 Filed on August 01, 2023
Income Statement
| Concept | 2023 Q3 | 2023 Q2 |
|---|---|---|
| Revenue | $33.97M | $25.79M |
| YoY Change | 78.97% | 36.86% |
| Cost Of Revenue | $13.40M | $6.786M |
| YoY Change | 105.96% | -26.05% |
| Gross Profit | $20.60M | $19.00M |
| YoY Change | 65.14% | 96.59% |
| Gross Profit Margin | 60.64% | 73.68% |
| Selling, General & Admin | $33.24M | $33.96M |
| YoY Change | 33.21% | 14.69% |
| % of Gross Profit | 161.36% | 178.73% |
| Research & Development | $14.89M | $22.10M |
| YoY Change | -48.92% | -31.86% |
| % of Gross Profit | 72.26% | 116.31% |
| Depreciation & Amortization | $30.00K | $51.00K |
| YoY Change | -71.43% | -66.0% |
| % of Gross Profit | 0.15% | 0.27% |
| Operating Expenses | $61.50M | $56.06M |
| YoY Change | 1.48% | -21.29% |
| Operating Profit | -$27.53M | -$37.06M |
| YoY Change | -33.85% | -29.25% |
| Interest Expense | $15.00M | -$14.44M |
| YoY Change | 5.95% | -201.2% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $1.278M | $1.560M |
| YoY Change | 93.93% | 390.57% |
| Pretax Income | -$41.30M | -$49.94M |
| YoY Change | -25.07% | -24.71% |
| Income Tax | $0.00 | $0.00 |
| % Of Pretax Income | ||
| Net Earnings | -$41.25M | -$49.94M |
| YoY Change | -25.16% | -24.71% |
| Net Earnings / Revenue | -121.43% | -193.65% |
| Basic Earnings Per Share | -$0.37 | -$0.46 |
| Diluted Earnings Per Share | -$0.37 | -$0.46 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 107.0M shares | 94.71M shares |
| Diluted Shares Outstanding | 111.9M shares | 109.2M shares |
Balance Sheet
| Concept | 2023 Q3 | 2023 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $114.8M | $138.5M |
| YoY Change | -39.37% | -25.49% |
| Cash & Equivalents | $114.8M | $138.5M |
| Short-Term Investments | $0.00 | $0.00 |
| Other Short-Term Assets | $9.300M | $7.180M |
| YoY Change | -18.49% | -24.87% |
| Inventory | $51.44M | $45.68M |
| Prepaid Expenses | ||
| Receivables | $42.62M | $40.80M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $218.2M | $232.1M |
| YoY Change | -16.64% | -8.06% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $6.000K | $2.445M |
| YoY Change | -97.66% | 577.29% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | ||
| YoY Change | ||
| Total Long-Term Assets | $3.078M | $2.501M |
| YoY Change | -93.97% | -95.14% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $218.2M | $232.1M |
| Total Long-Term Assets | $3.078M | $2.501M |
| Total Assets | $221.3M | $234.6M |
| YoY Change | -29.26% | -22.82% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $26.21M | $24.56M |
| YoY Change | 41.09% | 91.38% |
| Accrued Expenses | $54.80M | $44.20M |
| YoY Change | 36.71% | 4.13% |
| Deferred Revenue | $19.72M | $15.63M |
| YoY Change | 387.59% | 210.94% |
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $137.7M | $107.2M |
| YoY Change | 67.23% | 30.26% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $261.2M | $260.7M |
| YoY Change | 0.66% | 0.64% |
| Other Long-Term Liabilities | $232.4M | $238.7M |
| YoY Change | -12.33% | -6.15% |
| Total Long-Term Liabilities | $493.6M | $499.4M |
| YoY Change | -5.91% | -2.72% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $137.7M | $107.2M |
| Total Long-Term Liabilities | $493.6M | $499.4M |
| Total Liabilities | $631.3M | $606.6M |
| YoY Change | 4.02% | 1.83% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$1.493B | -$1.452B |
| YoY Change | 16.22% | 18.08% |
| Common Stock | $112.0K | $101.0K |
| YoY Change | 55.56% | 55.38% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | $55.00M | |
| YoY Change | 0.0% | |
| Treasury Stock Shares | ||
| Shareholders Equity | -$410.0M | -$372.0M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $221.3M | $234.6M |
| YoY Change | -29.26% | -22.82% |
Cashflow Statement
| Concept | 2023 Q3 | 2023 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$41.25M | -$49.94M |
| YoY Change | -25.16% | -24.71% |
| Depreciation, Depletion And Amortization | $30.00K | $51.00K |
| YoY Change | -71.43% | -66.0% |
| Cash From Operating Activities | -$19.32M | -$24.75M |
| YoY Change | -54.89% | -51.02% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | ||
| YoY Change | ||
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | $17.50M |
| YoY Change | -100.0% | 250.0% |
| Cash From Investing Activities | $0.00 | $17.50M |
| YoY Change | -100.0% | 250.0% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -4.310M | 809.0K |
| YoY Change | -109.31% | -95.53% |
| NET CHANGE | ||
| Cash From Operating Activities | -19.32M | -24.75M |
| Cash From Investing Activities | 0.000 | 17.50M |
| Cash From Financing Activities | -4.310M | 809.0K |
| Net Change In Cash | -23.63M | -6.441M |
| YoY Change | -164.81% | -76.51% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$19.32M | -$24.75M |
| Capital Expenditures | ||
| Free Cash Flow | ||
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2023Q2 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
54998000 | usd |
| CY2022Q4 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
54998000 | usd |
| CY2023Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.46 | |
| CY2023Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.46 | |
| CY2022Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.05 | |
| CY2022Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.05 | |
| CY2022Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
63227406 | shares |
| CY2022Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
63227406 | shares |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-323778000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
502000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2903000 | usd |
| CY2023Q1 | espr |
Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
|
52428000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
1000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-61719000 | usd |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
1000 | usd |
| CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3160000 | usd |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
4448000 | usd |
| CY2023Q2 | espr |
Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
|
10000 | usd |
| CY2023Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
1000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-49935000 | usd |
| CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-371978000 | usd |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-111654000 | usd | |
| us-gaap |
Depreciation
Depreciation
|
132000 | usd | |
| us-gaap |
Depreciation
Depreciation
|
303000 | usd | |
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
412000 | usd | |
| us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-372000 | usd | |
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
839000 | usd | |
| us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
800000 | usd | |
| espr |
Non Cash Interest Expense Related To Revenue Interest Liability
NonCashInterestExpenseRelatedToRevenueInterestLiability
|
22785000 | usd | |
| espr |
Non Cash Interest Expense Related To Revenue Interest Liability
NonCashInterestExpenseRelatedToRevenueInterestLiability
|
22228000 | usd | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
6063000 | usd | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
7963000 | usd | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
7070000 | usd | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
4910000 | usd | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-3712000 | usd | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-2754000 | usd | |
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
12127000 | usd | |
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-1078000 | usd | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
10475000 | usd | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-5162000 | usd | |
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1518000 | usd | |
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-4640000 | usd | |
| us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
3329000 | usd | |
| us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
4579000 | usd | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-79106000 | usd | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-89522000 | usd | |
| us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
0 | usd | |
| us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
18102000 | usd | |
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
42500000 | usd | |
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
5000000 | usd | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
42500000 | usd | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-13102000 | usd | |
| espr |
Payments From Revenue Interest Purchase Agreement
PaymentsFromRevenueInterestPurchaseAgreement
|
6616000 | usd | |
| espr |
Payments From Revenue Interest Purchase Agreement
PaymentsFromRevenueInterestPurchaseAgreement
|
3318000 | usd | |
| espr |
Proceeds From Issuance Of Common Stock Warrants And Pre Funded Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockWarrantsAndPreFundedWarrantsNetOfIssuanceCosts
|
52428000 | usd | |
| espr |
Proceeds From Issuance Of Common Stock Warrants And Pre Funded Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockWarrantsAndPreFundedWarrantsNetOfIssuanceCosts
|
0 | usd | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
4479000 | usd | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
20209000 | usd | |
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
10000 | usd | |
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
0 | usd | |
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
0 | usd | |
| us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
219000 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
50301000 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
16672000 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
13695000 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-85952000 | usd | |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
124775000 | usd |
| CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
258892000 | usd |
| CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
138470000 | usd |
| CY2022Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
172940000 | usd |
| espr |
Common Stock Issuance Costs Incurred Not Yet Paid
CommonStockIssuanceCostsIncurredNotYetPaid
|
31000 | usd | |
| espr |
Common Stock Issuance Costs Incurred Not Yet Paid
CommonStockIssuanceCostsIncurredNotYetPaid
|
36000 | usd | |
| espr |
Non Cash Right Of Use Asset
NonCashRightOfUseAsset
|
36000 | usd | |
| espr |
Non Cash Right Of Use Asset
NonCashRightOfUseAsset
|
12000 | usd | |
| CY2019Q3 | espr |
Number Of Study Patients
NumberOfStudyPatients
|
14000 | patient |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div> | ||
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of June 30, 2023 and December 31, 2022, eleven customers accounted for all of the Company's net trade receivables.</span></div> | ||
| espr |
Number Of Sources Of Revenue
NumberOfSourcesOfRevenue
|
2 | revenue_source | |
| CY2023Q2 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
43755000 | usd |
| CY2022Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
26558000 | usd |
| CY2023Q2 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
1007000 | usd |
| CY2022Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
6548000 | usd |
| CY2023Q2 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
914000 | usd |
| CY2022Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
2095000 | usd |
| CY2023Q2 | us-gaap |
Inventory Net
InventoryNet
|
45676000 | usd |
| CY2022Q4 | us-gaap |
Inventory Net
InventoryNet
|
35201000 | usd |
| CY2023Q1 | espr |
Potential Proceeds From Partner Milestone Payments
PotentialProceedsFromPartnerMilestonePayments
|
300000000 | usd |
| CY2023Q1 | espr |
Potential Proceeds From Partner Milestone Payments
PotentialProceedsFromPartnerMilestonePayments
|
300000000 | usd |
| CY2023Q2 | espr |
Potential Proceeds From Partner Milestone Payments
PotentialProceedsFromPartnerMilestonePayments
|
300000000 | usd |
| CY2023Q2 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
112511000 | usd |
| CY2023Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
0 | usd |
| CY2023Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
0 | usd |
| CY2023Q2 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
112511000 | usd |
| CY2022Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
152562000 | usd |
| CY2022Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
3000 | usd |
| CY2022Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
5000 | usd |
| CY2022Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
152560000 | usd |
| CY2022Q2 | us-gaap |
Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
|
0 | usd |
| CY2023Q2 | us-gaap |
Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
|
0 | usd |
| CY2023Q2 | us-gaap |
Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
|
0 | usd |
| espr |
Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
|
0 | usd | |
| CY2022Q2 | espr |
Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
|
0 | usd |
| espr |
Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
|
0 | usd | |
| CY2023Q2 | espr |
Fair Value Measurement Asset Transfers Between Levels
FairValueMeasurementAssetTransfersBetweenLevels
|
0 | usd |
| CY2022 | espr |
One Time Partial Call
OneTimePartialCall
|
50000000 | usd |
| CY2023Q2 | espr |
Revenue Interest Payments Redemption Percentage
RevenueInterestPaymentsRedemptionPercentage
|
2.25 | |
| CY2023Q2 | espr |
Revenue Interest Payments Redemption Value
RevenueInterestPaymentsRedemptionValue
|
400000000 | usd |
| CY2023Q2 | espr |
Revenue Interest Payments Remaining Redemption Value
RevenueInterestPaymentsRemainingRedemptionValue
|
381500000 | usd |
| CY2020Q4 | us-gaap |
Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
|
46000000 | usd |
| CY2020Q4 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
55000000 | usd |
| CY2020Q4 | us-gaap |
Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
|
46000000 | usd |
| CY2020Q4 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
55000000 | usd |
| CY2020Q4 | us-gaap |
Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
|
1994198 | shares |
| us-gaap |
Stock Issued During Period Shares Treasury Stock Reissued
StockIssuedDuringPeriodSharesTreasuryStockReissued
|
423272 | shares | |
| CY2023Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
6987000 | usd |
| CY2022Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
9053000 | usd |
| CY2023Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
4494000 | usd |
| CY2022Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
2547000 | usd |
| CY2023Q2 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
1325000 | usd |
| CY2022Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
1325000 | usd |
| CY2023Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
45000 | usd |
| CY2022Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
279000 | usd |
| CY2023Q2 | espr |
Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
|
12851000 | usd |
| CY2022Q4 | espr |
Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
|
13204000 | usd |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3842737 | shares |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
27.75 | |
| CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P4Y10M9D | |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
1658000 | usd |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1322300 | shares | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
3.86 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
691979 | shares | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
38.27 | ||
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | shares | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | ||
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4473058 | shares |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
19.06 | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y1M6D | ||
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
3000 | usd |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
4473058 | shares |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
19.06 | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P6Y1M6D | ||
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
3000 | usd |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
2422859 | shares |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
30.17 | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P3Y5M4D | ||
| CY2023Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
0 | usd |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd | |
| CY2022Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd | |
| CY2023Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
2900000 | usd |
| CY2023Q2 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
81002033 | shares |
| CY2022Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
36964286 | shares |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
86332196 | shares | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
51842215 | shares | |
| CY2023Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
138470000 | usd |
| CY2022Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
122940000 | usd |
| CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
124775000 | usd |
| CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
208892000 | usd |
| CY2023Q2 | us-gaap |
Restricted Cash
RestrictedCash
|
0 | usd |
| CY2022Q2 | us-gaap |
Restricted Cash
RestrictedCash
|
50000000 | usd |
| CY2022Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
0 | usd |
| CY2021Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
50000000 | usd |
| CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
138470000 | usd |
| CY2022Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
172940000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
124775000 | usd |
| CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
258892000 | usd |
